About This Role: As the Senior Manager, CMC Operations, you will be an essential operational leader within our Early Phase Development & Manufacturing team. Your primary responsibility will be overseeing external development and manufacturing activities from
Date Posted:2026-09-03 Country:United States of America Location:US-MA-CAMBRIDGE-BBN01 ~ 10 & 50 Moulton St ~ MOULTON B2 Position Role Type:Hybrid U.S. Citizen, U.S. Person, or Immigration Status Requirements: The ability to obtain and maintain a U.S. government
Date Posted:2026-09-08 Country:United States of America Location:US-MA-CAMBRIDGE-555-CUST ~ 555 Technology Sq ~ TECHNOLOGY (External Site) Position Role Type:Onsite U.S. Citizen, U.S. Person, or Immigration Status Requirements: Active and transferable U.S. government issued security clearance is required
Date Posted:2026-09-08 Country:United States of America Location:US-MA-CAMBRIDGE-555-CUST ~ 555 Technology Sq ~ TECHNOLOGY (External Site) Position Role Type:Onsite U.S. Citizen, U.S. Person, or Immigration Status Requirements: Active and transferable U.S. government issued security clearance is required
Cullinan Therapeutics (NASDAQ: CGEM) is a clinical-stage biotech company developing potential first- or best-in-class, high-impact molecules in autoimmune diseases and cancer, where exceptional scientific expertise, strategic risk-taking, and rigorous decision-making unite to improve peoples’ lives. We
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms
At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to
Why Sarepta? Why Now? The promise of genetic medicine has arrived, and Sarepta is at the forefront. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across